Literature DB >> 31286523

Local recurrence of Ewing sarcoma: Is wide excision an acceptable treatment?

Ruifeng Xue1, Valerae O Lewis1, Bryan S Moon1, Patrick P Lin1.   

Abstract

BACKGROUND AND OBJECTIVES: Local recurrence in Ewing sarcoma (ES) is associated with poor prognosis. The purpose of the study is to determine what factors affect overall survival after local recurrence and whether wide excision constitutes appropriate treatment.
METHODS: From 1992 to 2017, 26 patients were treated for local recurrence of ES. Sixteen patients presented with local recurrence only while 10 had metastasis. The median follow-up was 23 months (range, 3-255 months). Overall survival was assessed with Kaplan-Meier analysis.
RESULTS: At the last follow-up, seven of 26 (27%) patients were alive. Overall survival after local recurrence was 28% at 5 years. Later onset of local recurrence (P = .041), surgical treatment (P < .001), and complete eradication of all recurrent disease (P < .001) predicted better survival. Metastasis was associated with worse survival (P = .014). All three patients who survived more than 10 years were treated with wide local excision. A second local recurrence developed in seven patients (28%) but did not predict worse overall survival.
CONCLUSIONS: Overall survival after local recurrence is better for patients with nonmetastatic disease treated surgically. Wide excision can be compatible with long survival. We do not advocate amputation on a routine basis for local recurrence. Complete eradication of all diseases is associated with better survival.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  Ewing sarcoma; amputation; chemotherapy; local recurrence; radiation therapy; surgical resection

Mesh:

Year:  2019        PMID: 31286523     DOI: 10.1002/jso.25615

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  3 in total

1.  Standard Treatment Remains the Recommended Approach for Patients with Bone Sarcoma Who Underwent Unplanned Surgery: Report from the Japanese Musculoskeletal Oncology Group.

Authors:  Tomoki Nakamura; Jun Sugaya; Norifumi Naka; Hiroshi Kobayashi; Tomotake Okuma; Toshiyuki Kunisada; Kunihiro Asanuma; Hedetatsu Outani; Shunji Nishimura; Hiroyuki Kawashima; Toru Akiyama; Taketoshi Yasuda; Shinji Miwa; Akihiro Sudo; Takafumi Ueda
Journal:  Cancer Manag Res       Date:  2020-10-12       Impact factor: 3.989

2.  CORR Insights®: Which Factors Are Associated with Local Control and Survival of Patients with Localized Pelvic Ewing's Sarcoma? A Retrospective Analysis of Data from the Euro-EWING99 Trial.

Authors:  Steven Gitelis
Journal:  Clin Orthop Relat Res       Date:  2020-02       Impact factor: 4.755

3.  EWS-FLI1-targeting peptide identifies Ewing sarcoma tumor boundaries and lymph node metastasis via near-infrared imaging.

Authors:  Yu Wang; Hengtang Mai; Ying Yuan; Hairen Chen; Song Wu; Xiang Hu; Aixi Yu
Journal:  Mol Oncol       Date:  2021-08-30       Impact factor: 6.603

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.